Postdoc.
Laboratory: Lab of Phenotypic Screening
Email: yanlei1@shanghaitech.edu.cn
Education & Work Experiences:
2024.7- Postdoctor, SIAIS, ShanghaiTech University.
2024.01-2024.06 Engineer, Eobiont.
2020.08-2023.12 Postdoc, Center for Excellence in Molecular and Cellular Sciences, Chinese Academy of Sciences.
2014.09-2020.07 Ph.D of Science in Molecular biology, University of China Academy of Sciences (Joint Program with ShanghaiTech University).
2010.09-2014.06 Bachelor of Pharmaceutical Engineering, China Pharmaceutical University.
Research Expertise:
Molecular and Cell Biology: Cloning; Protein Expression and Purification; Western Blot; Cell Culture; Microscopy; FACS; Immunofluorescence.
Biophysics: Protein Crystallization; Diffraction Data Collection; Protein Structure determination through Molecular Replacement.
Selected Awards and Honors:
1.National scholarship, 2019
2.Outstanding member of Communist Party of ShanghaiTech University, 2016
Conference Presentations and Posters:
Poster:
Molecular characterization of a versatile peptide that blocks the cellular entry of highly contagious CoVs, 3rd ShanghaiTech-SIAIS Bioforum, 11/2016
Molecular characterization of a versatile peptide that blocks the cellular entry of highly contagious CoVs, Cold Spring Harbor Meeting, 4/2017
Publications:
1. Yan L, Wang F, Hill M, Brun J, Liang Z, Shi X, Zhang L, He X, Li Y, Huang Q, Dong X, Liu H, Zhang Y, Liu L, Dwek RA, Zitzmann N, Liang A, Yang G. A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses. Nat Commun. 2025 Aug 15;16(1):7580. (First author)
2. He X, Liu H, Yang G, Yan L. Structures of HCoV-OC43 HR1 Domain in Complex with Cognate HR2 or Analogue EK1 Peptide. Viruses. 2025 Feb 28;17(3):343. (Corresponding author)
3. Wang F, Yang G, Yan L. Crystal Structures of Fusion Cores from CCoV-HuPn-2018 and SADS-CoV. Viruses. 2024 Feb 9;16(2):272. (Corresponding author)
4. Li W, Wang F, Li Y, Yan L, Liu L, Zhu W, Ma P, Shi X, Yang G. Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System. Vaccines. 2023 Mar 31;11(4):771.
5. Shi X, Wan Y, Wang N, Xiang J, Wang T, Yang X, Wang J, Dong X, Dong L, Yan L, Li Y, Liu L, Hou S, Zhong Z, Wilson IA, Yang B, Yang G, Lerner RA. Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms. Nat Commun. 2021 May 5;12(1):2547.
6. Shi X, Li Y, Yan L, Yang G, Qiang M. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2021 Jan;50:102125.
7. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 Apr 10;5(4):eaav4580. (co-first author)
8. Yan L, Meng B, Xiang J, Wilson IA, Yang B. Crystal structure of the post-fusion core of the Human coronavirus 229E spike protein at 1.86 Å resolution. Acta Crystallogr D Struct Biol. 2018 Sep 1;74(Pt 9):841-851. (First author)
9. Lei L, Chen H, Xue W, Yang B, Hu B, Wei J, Wang L, Cui Y, Li W, Wang J, Yan L, Shang W, Gao J, Sha J, Zhuang M, Huang X, Shen B, Yang L, Chen J. APOBEC3 induces mutations during repair of CRISPR-Cas9-generated DNA breaks. Nat Struct Mol Biol. 2018 Jan;25(1):45-52.
10.Wang L, Xue W, Yan L, Li X, Wei J, Chen M, Wu J, Yang B, Yang L, Chen J. Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor. Cell Res. 2017 Oct;27(10):1289-1292. (co-first author)
中文简介
严磊博士于2010年至2014年在中国药科大学获得制药工程工学学士学位，随后于2014年至2020年在中国科学院大学（与上海科技大学联合培养项目，硕博连读）获得分子生物学理学博士学位。2020年8月至2023年12月在中国科学院分子细胞科学卓越科创中心从事博士后研究，并于2024年初在上海优拜天成担任工程师，后于2024年7月加入上海科技大学免疫化学研究所继续从事博士后研究。研究工作主要聚焦于利用结构生物学、抗体工程与合成免疫学等技术手段，探究病毒（尤其是冠状病毒）的入侵机制，并开发相应的广谱治疗性抗体与多肽抑制剂。其在冠状病毒高度保守的HR1（七肽重复序列1）结构域的研究中取得了系列重要成果：作为第一作者在Nature Communications上报道了一种能够识别冠状病毒HR1区域共同特征模序的广谱中和抗体，并揭示了其独特的作用机制；系统性阐释了靶向病毒保守表位的抗体其广谱反应性与中和活性的结构基础，这些研究为应对新发冠状病毒及病毒变异提供了潜在干预策略，展现了其研究工作的基础探索与转化应用价值。此外，通过解析多种冠状病毒（如HCoV-229E[Acta Crystallogr D Struct Biol. 2018], HCoV-OC43[Viruses. 2025], CCoV-HuPn-2018及SADS-CoV[Viruses. 2024]）刺突蛋白融合核心或HR1结构域的三维结构，为理解病毒膜融合机制及设计泛冠状病毒融合抑制剂（如参与开发的EK1多肽[Science Advances. 2019]）提供了关键结构基础。
